IL298730A - סיווג רשומה רפואית אלקטרונית מבוסס (ehr) עבור סוג משנה של תסמונת מצוקה נשימתית חריפה (ards) - Google Patents
סיווג רשומה רפואית אלקטרונית מבוסס (ehr) עבור סוג משנה של תסמונת מצוקה נשימתית חריפה (ards)Info
- Publication number
- IL298730A IL298730A IL298730A IL29873022A IL298730A IL 298730 A IL298730 A IL 298730A IL 298730 A IL298730 A IL 298730A IL 29873022 A IL29873022 A IL 29873022A IL 298730 A IL298730 A IL 298730A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- subphenotype
- patient
- mortality
- classifier
- Prior art date
Links
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title claims description 385
- 230000036541 health Effects 0.000 title claims description 59
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 346
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 345
- 238000011282 treatment Methods 0.000 claims description 311
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 288
- 206010029315 Neuromuscular blockade Diseases 0.000 claims description 228
- 238000002560 therapeutic procedure Methods 0.000 claims description 212
- 210000002216 heart Anatomy 0.000 claims description 198
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 184
- 238000000034 method Methods 0.000 claims description 168
- 230000004872 arterial blood pressure Effects 0.000 claims description 144
- 229940109239 creatinine Drugs 0.000 claims description 144
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 139
- 229910052760 oxygen Inorganic materials 0.000 claims description 139
- 239000001301 oxygen Substances 0.000 claims description 139
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 135
- 238000012549 training Methods 0.000 claims description 134
- 230000036387 respiratory rate Effects 0.000 claims description 113
- 230000036961 partial effect Effects 0.000 claims description 100
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 86
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 86
- 238000004422 calculation algorithm Methods 0.000 claims description 71
- 239000000090 biomarker Substances 0.000 claims description 63
- 239000012530 fluid Substances 0.000 claims description 59
- 230000007115 recruitment Effects 0.000 claims description 51
- 230000002829 reductive effect Effects 0.000 claims description 48
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 47
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 claims description 44
- 229950011606 lisofylline Drugs 0.000 claims description 44
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 43
- 239000001569 carbon dioxide Substances 0.000 claims description 43
- 238000003860 storage Methods 0.000 claims description 40
- 230000001747 exhibiting effect Effects 0.000 claims description 38
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 38
- 229940124572 antihypotensive agent Drugs 0.000 claims description 37
- 229960003957 dexamethasone Drugs 0.000 claims description 37
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 37
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 37
- 241001123248 Arma Species 0.000 claims description 32
- 238000003745 diagnosis Methods 0.000 claims description 32
- 238000010801 machine learning Methods 0.000 claims description 32
- 102000004889 Interleukin-6 Human genes 0.000 claims description 31
- 108090001005 Interleukin-6 Proteins 0.000 claims description 31
- -1 arterial pH Chemical compound 0.000 claims description 30
- 230000015654 memory Effects 0.000 claims description 29
- 238000004393 prognosis Methods 0.000 claims description 29
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 28
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 28
- 230000036772 blood pressure Effects 0.000 claims description 28
- 229960004125 ketoconazole Drugs 0.000 claims description 28
- 229960004584 methylprednisolone Drugs 0.000 claims description 28
- 238000009423 ventilation Methods 0.000 claims description 28
- 239000003246 corticosteroid Substances 0.000 claims description 25
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 24
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 24
- 102000003814 Interleukin-10 Human genes 0.000 claims description 24
- 108090000174 Interleukin-10 Proteins 0.000 claims description 24
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 24
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims description 24
- 102100036537 von Willebrand factor Human genes 0.000 claims description 24
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 23
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 23
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 23
- 229960001134 von willebrand factor Drugs 0.000 claims description 23
- 102000004890 Interleukin-8 Human genes 0.000 claims description 22
- 108090001007 Interleukin-8 Proteins 0.000 claims description 22
- 210000001147 pulmonary artery Anatomy 0.000 claims description 21
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 20
- 229910052700 potassium Inorganic materials 0.000 claims description 20
- 239000011591 potassium Substances 0.000 claims description 20
- 230000035487 diastolic blood pressure Effects 0.000 claims description 19
- 230000001228 trophic effect Effects 0.000 claims description 17
- 229910003798 SPO2 Inorganic materials 0.000 claims description 14
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 claims description 14
- 241000220317 Rosa Species 0.000 claims description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 6
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 6
- 238000004458 analytical method Methods 0.000 description 62
- 230000004083 survival effect Effects 0.000 description 59
- 230000000241 respiratory effect Effects 0.000 description 58
- 230000004044 response Effects 0.000 description 54
- 230000006870 function Effects 0.000 description 48
- 238000010200 validation analysis Methods 0.000 description 47
- 238000003064 k means clustering Methods 0.000 description 40
- 230000000694 effects Effects 0.000 description 36
- 238000007477 logistic regression Methods 0.000 description 36
- 238000012360 testing method Methods 0.000 description 29
- 230000008901 benefit Effects 0.000 description 26
- 229940100601 interleukin-6 Drugs 0.000 description 23
- 108010048233 Procalcitonin Proteins 0.000 description 21
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 21
- 230000003993 interaction Effects 0.000 description 20
- 238000009826 distribution Methods 0.000 description 19
- 229940076144 interleukin-10 Drugs 0.000 description 18
- 206010040047 Sepsis Diseases 0.000 description 16
- 229940096397 interleukin-8 Drugs 0.000 description 16
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 15
- 206010035664 Pneumonia Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000000926 separation method Methods 0.000 description 14
- 238000013528 artificial neural network Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000004590 computer program Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 10
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 10
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 10
- 229960005370 atorvastatin Drugs 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229960002855 simvastatin Drugs 0.000 description 10
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 10
- 230000008733 trauma Effects 0.000 description 10
- 238000003066 decision tree Methods 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 description 8
- 230000000306 recurrent effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- 238000004820 blood count Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 238000007637 random forest analysis Methods 0.000 description 6
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 5
- 101000867205 Escherichia coli Heat-stable enterotoxin ST-2 Proteins 0.000 description 5
- 238000012042 bayesian logistic regression model Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 244000118350 Andrographis paniculata Species 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 4
- 241000109329 Rosa xanthina Species 0.000 description 4
- 235000004789 Rosa xanthina Nutrition 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000013527 convolutional neural network Methods 0.000 description 4
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 230000002232 neuromuscular Effects 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010206 sensitivity analysis Methods 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 238000012706 support-vector machine Methods 0.000 description 4
- 230000003519 ventilatory effect Effects 0.000 description 4
- 206010003504 Aspiration Diseases 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 208000018875 hypoxemia Diseases 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005399 mechanical ventilation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011176 pooling Methods 0.000 description 3
- 238000013105 post hoc analysis Methods 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 201000004193 respiratory failure Diseases 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 229910000906 Bronze Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 238000000342 Monte Carlo simulation Methods 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000010974 bronze Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000002939 cerumen Anatomy 0.000 description 2
- 238000004138 cluster model Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004909 pre-ejaculatory fluid Anatomy 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000010207 Bayesian analysis Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 101150004790 SUB8 gene Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013499 data model Methods 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012880 independent component analysis Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioethics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Artificial Intelligence (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034368P | 2020-06-03 | 2020-06-03 | |
| US202063064054P | 2020-08-11 | 2020-08-11 | |
| US202163180880P | 2021-04-28 | 2021-04-28 | |
| PCT/US2021/035638 WO2021247819A1 (en) | 2020-06-03 | 2021-06-03 | Electronic health record (ehr)-based classifier for acute respiratory distress syndrome (ards) subtyping |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298730A true IL298730A (he) | 2023-02-01 |
Family
ID=78830558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298730A IL298730A (he) | 2020-06-03 | 2021-06-03 | סיווג רשומה רפואית אלקטרונית מבוסס (ehr) עבור סוג משנה של תסמונת מצוקה נשימתית חריפה (ards) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230290452A1 (he) |
| EP (1) | EP4162065A4 (he) |
| JP (1) | JP2023529647A (he) |
| AU (1) | AU2021283365A1 (he) |
| CA (1) | CA3181163A1 (he) |
| IL (1) | IL298730A (he) |
| MX (1) | MX2022015408A (he) |
| WO (1) | WO2021247819A1 (he) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11476003B2 (en) * | 2020-12-15 | 2022-10-18 | Biodesix, Inc. | Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings |
| EP4370020A4 (en) * | 2021-07-16 | 2025-04-30 | Johnson & Johnson Enterprise Innovation Inc. | System and method for predicting the risk of future lung cancer |
| US20230260613A1 (en) * | 2022-02-11 | 2023-08-17 | Siemens Healthcare Gmbh | Ai-driven care planning using single-subject multi-modal information |
| WO2023175059A1 (en) * | 2022-03-17 | 2023-09-21 | Koninklijke Philips N.V. | Predicting and stratififying acute respiratory distress syndrome |
| US20230352134A1 (en) * | 2022-04-04 | 2023-11-02 | Cvs Pharmacy, Inc. | Ai based systems and methods for providing a care plan |
| CN115240854B (zh) * | 2022-07-29 | 2023-10-03 | 中国医学科学院北京协和医院 | 一种胰腺炎预后数据的处理方法及其系统 |
| US20240047070A1 (en) * | 2022-08-04 | 2024-02-08 | Optum, Inc. | Machine learning techniques for generating cohorts and predictive modeling based thereof |
| CN115804585B (zh) * | 2023-02-08 | 2023-06-13 | 浙江大学 | 一种基于机械通气波形检测气道高阻力的方法及系统 |
| KR102834831B1 (ko) * | 2023-03-29 | 2025-07-17 | 재단법인 아산사회복지재단 | 급성호흡곤란증후군의 아표현형 진단용 신규 바이오 마커 |
| WO2025064666A1 (en) * | 2023-09-19 | 2025-03-27 | Gen1E Lifesciences Inc. | Machine learning methods and systems for acute respiratory distress syndrome patient sub-phenotyping |
| EP4557308A1 (en) * | 2023-11-17 | 2025-05-21 | Universidad de Valladolid | Evaluation system for establishing risk phenotypes on prehospital care |
| CN120236776B (zh) * | 2025-05-29 | 2025-10-10 | 陕西省人民医院(陕西省临床医学研究院) | 基于医疗信息处理的脓毒症患者监测系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10126295B2 (en) * | 2014-03-21 | 2018-11-13 | National Jewish Health | Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis |
| WO2016022974A1 (en) * | 2014-08-07 | 2016-02-11 | Children's Medical Center Corporation | Computer aided mechanical ventilation systems and methods |
| AU2017357809B2 (en) * | 2016-11-11 | 2022-09-08 | The Regents Of The University Of California | Resuscitation and ventilation asynchrony monitor |
| US20200178903A1 (en) * | 2018-12-10 | 2020-06-11 | General Electric Company | Patient monitoring system and method having severity prediction and visualization for a medical condition |
| US11651850B2 (en) * | 2019-12-20 | 2023-05-16 | The Regents Of The University Of Michigan | Computer vision technologies for rapid detection |
| US20210301006A1 (en) * | 2020-03-30 | 2021-09-30 | Fibrogen, Inc | Methods of treating acute respiratory distress syndrome |
-
2021
- 2021-06-03 AU AU2021283365A patent/AU2021283365A1/en not_active Abandoned
- 2021-06-03 CA CA3181163A patent/CA3181163A1/en active Pending
- 2021-06-03 EP EP21815885.5A patent/EP4162065A4/en active Pending
- 2021-06-03 MX MX2022015408A patent/MX2022015408A/es unknown
- 2021-06-03 IL IL298730A patent/IL298730A/he unknown
- 2021-06-03 WO PCT/US2021/035638 patent/WO2021247819A1/en not_active Ceased
- 2021-06-03 US US18/007,608 patent/US20230290452A1/en active Pending
- 2021-06-03 JP JP2022574663A patent/JP2023529647A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4162065A4 (en) | 2024-06-26 |
| CA3181163A1 (en) | 2021-12-09 |
| JP2023529647A (ja) | 2023-07-11 |
| EP4162065A1 (en) | 2023-04-12 |
| WO2021247819A1 (en) | 2021-12-09 |
| MX2022015408A (es) | 2023-03-22 |
| AU2021283365A1 (en) | 2023-02-02 |
| US20230290452A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230290452A1 (en) | Electronic Health Record (EHR)-Based Classifier for Acute Respiratory Distress Syndrome (ARDS) Subtyping | |
| Zhang et al. | Machine learning for the prediction of volume responsiveness in patients with oliguric acute kidney injury in critical care | |
| Hamada et al. | Development and validation of a pre-hospital “Red Flag” alert for activation of intra-hospital haemorrhage control response in blunt trauma | |
| Ghassemi et al. | Predicting intervention onset in the ICU with switching state space models | |
| Mofidi et al. | Identification of severe acute pancreatitis using an artificial neural network | |
| Zhang et al. | Developing an ensemble machine learning model for early prediction of sepsis-associated acute kidney injury | |
| CN107111603A (zh) | 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型 | |
| JP2019511057A (ja) | Ｓｉｒｓの予測のための臨床パラメータの使用 | |
| US20230054069A1 (en) | Systems and methods for predicting kidney function decline | |
| CN111640512B (zh) | 肾脏替代疗法启动策略评估方法、装置及电子设备 | |
| CN114566284A (zh) | 疾病预后风险预测模型训练方法、装置及电子设备 | |
| Wang et al. | A time-series feature-based recursive classification model to optimize treatment strategies for improving outcomes and resource allocations of COVID-19 patients | |
| Soussi et al. | Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials | |
| Rhee et al. | Machine learning-based discrimination of cardiovascular outcomes in patients with hypertrophic cardiomyopathy | |
| CN114613517A (zh) | 一种预后预测方法及装置、电子设备、存储介质 | |
| Mochizuki et al. | Acidemia subtypes in critically ill patients: An international cohort study | |
| Giordano et al. | Predictive models in extracorporeal membrane oxygenation (ECMO): a systematic review | |
| Hui et al. | Using machine learning to predict bleeding after cardiac surgery | |
| CN120126775A (zh) | 一种急性胰腺炎患者合并内脏静脉血栓的风险预测系统 | |
| Tan et al. | Advances in the clinical application of machine learning in acute pancreatitis: a review | |
| Choi et al. | Prognostic prediction of sepsis patient using transformer with skip connected token for tabular data | |
| Lezcano et al. | Predictors of mechanical ventilation and mortality in critically ill patients with COVID-19 pneumonia | |
| Reddi et al. | Abnormal pulmonary function tests are associated with prolonged ventilation and risk of complications following elective cardiac surgery | |
| Willers et al. | HEROES V‐A: HEmoRrhagic cOmplications in veno‐arterial Extracorporeal life Support: Development and internal validation of a multivariable prediction model in adult patients | |
| CN114783587A (zh) | 严重急性肾损伤智能预测系统 |